Revenue

Treace Medical heads to the J.P. Morgan conference to showcase its surgical tech, facing tough questions on growth amid competition and market shifts.

INVO Fertility realigns its top brass, positioning a deal-making veteran to lead an aggressive clinic acquisition strategy in a booming market.

As 10x Genomics preps for its J.P. Morgan spotlight, investors seek a clear path to profit amid fierce competition and groundbreaking innovation.

Sidus Space nets nearly $15M in a new offering to scale satellite production and defense tech, sparking investor optimism despite financial pressures.

Hyatt finalizes a $2B asset sale to Tortuga Resorts, advancing its asset-light strategy while navigating hurricane recovery in the Caribbean.

Investors await Polaris's Q4 results on Jan. 27, seeking clarity on market share gains, tariff impacts, and the future of its Indian Motorcycle brand.

Amidst legal industry fears of generative AI, BriefCatch's $6M funding and stellar retention prove the value of a trusted, specialized AI writing partner.

With CEO David Endicott set to present at the J.P. Morgan Healthcare Conference, all eyes are on Alcon's strategy for innovation and market growth.

Emmaus Life Sciences outsources its sickle cell drug Endari® in North America to focus on global growth, as NeoImmuneTech gains a key U.S. market foothold.

KORU Medical seeks FDA clearance for its FreedomEDGE® system with a key breast cancer drug, signaling a major shift in cancer care delivery.

Amid market volatility and a green energy push, Devon's CEO will outline the firm's strategy for navigating a complex 2026 at a top industry event.

Fitch Ratings awards NETSTREIT a BBB- rating, a milestone affirming its conservative strategy and unlocking new avenues for growth and capital efficiency.

Facing market headwinds, tea supplier Oriental Rise makes a bold move to acquire a major producer, aiming to secure its supply chain and boost quality.

PacBio heads to J.P. Morgan's conference with new tech aimed at making long-read sequencing cheaper. Can it challenge rivals and win over investors?

SOLAI shareholders approved a massive 30 billion share increase, arming the firm for a radical pivot into AI and the Solana ecosystem. But what about dilution?

As Axos sets to reveal its Q2 results, investors weigh strong growth forecasts against mounting concerns over margin pressure and a shifting economy.

Amid economic headwinds, the M&A advisor thrived by securing over 90 deals and promoting key partners, signaling strong momentum for healthcare sales in 2026.

With a new $500 million credit line, Ramaco Resources is doubling down on its unique strategy: growing its coal business while racing to develop a US rare earth mine.

As data centers face an energy crisis fueled by AI, Aradatum is commercializing a unique vertical wind turbine promising a dense, low-cost power solution.

Fresh off a successful IPO, Ceribell is set to showcase its revolutionary AI-powered EEG system, a device already changing outcomes in ICUs nationwide.